JFL Life Sciences (NSE:JFLLIFE) EBIT: ₹71.3 Mil (TTM As of Mar. 2025)


NSE:JFLLIFE JFL Life Sciences Ltd NSE:JFLLIFE
65 GF Score
Price ₹9.05
GF Value ₹35.55
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is JFL Life Sciences EBIT?

JFL Life Sciences NSE:JFLLIFE 65 EBIT is ₹71.3 Mil as of Mar. 2025. GuruFocus rates NSE:JFLLIFE with a GF Score™ of 65/100 and a GF Value™ of ₹35.55 (Significantly Undervalued). The stock has 2 warning signs investors should review.

JFL Life Sciences's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2025 was ₹71.3 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2025 was ₹71.3 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. JFL Life Sciences's annualized ROC % for the quarter that ended in Mar. 2025 was 10.39%. JFL Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 15.61%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. JFL Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 17.04%.

JFL Life Sciences  (NSE:JFLLIFE) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

JFL Life Sciences's annualized ROC % for the quarter that ended in Mar. 2025 is calculated as:

ROC % (Q: Mar. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2024 ) + Invested Capital (Q: Mar. 2025 ))/ count )
=72.065 * ( 1 - 32.22% )/( (424.144 + 515.892)/ 2 )
=48.845657/470.018
=10.39 %

where

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=567.103 - 142.618 - ( 0.341 - max(0, 206.282 - 436.022+0.341))
=424.144

Invested Capital(Q: Mar. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=719.14 - 202.909 - ( 0.339 - max(0, 316.215 - 595.04+0.339))
=515.892

Note: The Operating Income data used here is one times the annual (Mar. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

JFL Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2024  Q: Mar. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=71.282/( ( (128.334 + max(282.026, 0)) + (122.363 + max(380.574, 0)) )/ 2 )
=71.282/( ( 410.36 + 502.937 )/ 2 )
=71.282/456.6485
=15.61 %

where Working Capital is:

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(258.466 + 158.333 + 18.609) - (142.618 + 0 + 10.764)
=282.026

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(349.451 + 232.411 + 12.823) - (202.909 + 0 + 11.202)
=380.574

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Mar. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

JFL Life Sciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2025 )
=71.282/418.390
=17.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JFL Life Sciences EBIT Related Terms

JFL Life Sciences EBIT Historical Data

* Premium members only.

The historical data trend for JFL Life Sciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JFL Life Sciences EBIT Chart

JFL Life Sciences Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
EBIT
Get a 7-Day Free Trial 19.74 58.50 50.42 45.36 71.28

JFL Life Sciences Semi-Annual Data
Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
EBIT Get a 7-Day Free Trial 19.74 58.50 50.42 45.36 71.28

NSE:JFLLIFE vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, JFL Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

JFL Life Sciences EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, JFL Life Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where JFL Life Sciences's EV-to-EBIT falls into.


NSE:JFLLIFE
65GF Score
JFL Life Sciences Ltd NSE:JFLLIFE
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

JFL Life Sciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was ₹71.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹71.3 Mil mean?
JFL Life Sciences (NSE:JFLLIFE) has a EBIT of ₹71.3 Mil as of Mar. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on JFL Life Sciences.
Is JFL Life Sciences' EBIT too high?
JFL Life Sciences' current EBIT is ₹71.3 Mil. Overall, JFL Life Sciences has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JFL Life Sciences' EBIT compare to ZTS?
JFL Life Sciences' EBIT of ₹71.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on JFL Life Sciences. JFL Life Sciences's current EBIT is ₹71.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JFL Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, JFL Life Sciences (NSE:JFLLIFE) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹35.55, compared to a current price of ₹9.05 — trading 74.5% below its estimated fair value. The current EBIT is ₹71.3 Mil. JFL Life Sciences' overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For JFL Life Sciences (NSE:JFLLIFE), the current EBIT is ₹71.3 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is JFL Life Sciences (NSE:JFLLIFE) Overvalued in 2026?

Based on GuruFocus' analysis, JFL Life Sciences stock appears to be undervalued. The current stock price of ₹9.05 is trading 74.5% below its estimated GF Value™ of ₹35.55. GuruFocus considers JFL Life Sciences to be Significantly Undervalued.

Key valuation signals for NSE:JFLLIFE:

  • EBIT: ₹71.3 Mil
  • GF Value™: ₹35.55 vs. price of ₹9.05 (74.5% below fair value)
  • GF Score™: 65/100 with 2 warning signs

No single metric tells the full story. See the NSE:JFLLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

JFL Life Sciences Business Description

Address Jodhpur Cross Road, 309, Satyam Mall, Opposite Saman Complex, Near Vishweshwar Mahadev Mandir, Settelite, Ahmedabad, GJ, IND, 380015
JFL Life Sciences Ltd is engaged in the business of manufacturing pharmaceutical products. The company's product portfolio consists of Dry powder injections (B-Lactam), Tablets and Capsules (B-Lactam) solid oral dosage forms, and general tablets and capsules. Its operating segment comprises of manufacturing and selling of pharmaceutical products. Geographically, the company sells its products both in India and outside India.
65GF Score

Get the complete analysis for NSE:JFLLIFE

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹9.05
Price
₹35.55
GF Value